Potassium channel opener
A potassium channel opener including a compound (e.g., pimaric acid) represented by the formula [I]: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde, or nitrile; or R 4 and R 5 may be bonded to each other to form a ring; or R 6 and R 7 may be bonded to each other to form a ring; and all of three bonds represented by are single bonds, or one of the three bonds is double bond and the other bonds are single bonds, or a physiologically acceptable salt thereof as an effective ingredient.
1. A method of treatment of hypertension including essential hypertension, tonic bladder, disturbances of peripheral circulation, airway hyper-responsiveness, sensory neuron hypersensitivity, central spasm, or ischemic central nervous system disorder, which comprises administering an effective amount of a compound represented by the formula [I]:
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently a hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde or nitrile; or R 4 and R 5 are bonded to each other to form a ring; or R 6 and R 7 are bonded to each other to form a ring;
and all of three bonds represented by are single bonds, or one of the three bonds is double bond and the other bonds are single bonds,
or a physiologically acceptable salt thereof,
to a mammal in need thereof.
2. The method according to claim 1 , wherein the compound is a compound represented by the formula:
wherein R 2 is a hydroxy, hydroxyalkyl, aminoalkyl, alkoxy, acyl, carboxyl, hydroxamate, sulfo, carbamoyl, sulfonamide or nitrile;
R 1 , R 3 , R 4 , R 5 , R 6 and R 7 are each independently a hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde or nitrile; or R 4 and R 5 are bonded to each other to form a ring; or R 6 and R 7 are bonded to each other to form a ring; and
all of three bonds represented by are single bonds, or one of the three bonds is a double bond and the other bonds are single bonds.
3. The method according to claim 1 or 2 , wherein R 1 , R 3 , R 4 and R 5 are each alkyl or alkenyl, R 6 and R 7 are each hydrogen and R 2 is carboxyl, or a physiologically acceptable salt thereof.
4. The method according to claim 1 or 2 , wherein the compound is a substance selected from the group consisting of the following compounds: (1) a compound wherein R 1 is alkyl, R 2 is carboxyl, R 3 is alkyl, R 4 is alkenyl, R 5 is alkyl, and R 6 and R 7 are hydrogen, (2) a compound wherein R 1 is alkyl, R 2 is carboxyl, R 3 is alkyl, R 4 is alkyl, R 5 is alkenyl, and R 6 and R 7 are hydrogen, and (3) a compound wherein R 1 is alkyl, R 2 is carboxyl, R 3 is alkyl, R 4 is alkyl, R 5 is alkyl, and R 6 and R 7 are hydrogen, or a physiologically acceptable salt thereof.
5. The method according to claim 1 , wherein the compound is a substance selected from the group consisting of pimaric acid, dihydropimaric acid, dihydroisopimarinol, sandaracopimaric acid, isopimaric acid, and dihydroisopimaric acid, or a physiologically acceptable salt thereof.
6. The method according to claim 1 , said method treats essential hypertension, tonic bladder, airway hyper-responsiveness, or ischemic central nervous system disorder.